Abstract Background Cell cycle dysregulation is common in human malignancies. and CDK4/6 inhibitors targeting cell cycle have potential antitumor activity. SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. However. https://www.jalyttlers.shop/product-category/tea-cosy/